Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success.

Burton R, Puthoor M, Fyles F, Lewis L, Joplin H, Burhan H

Open source

DOI
10.1136/bmjresp-2026-004232
Published
2026 Jul 31
Container
BMJ open respiratory research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjresp-2026-004232,
  title = {Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success.},
  author = {Burton R and Puthoor M and Fyles F and Lewis L and Joplin H and Burhan H},
  year = {2026},
  journal = {BMJ open respiratory research},
  doi = {10.1136/bmjresp-2026-004232},
  url = {https://doi.org/10.1136/bmjresp-2026-004232}
}

RIS

TY  - JOUR
TI  - Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success.
AU  - Burton R
AU  - Puthoor M
AU  - Fyles F
AU  - Lewis L
AU  - Joplin H
AU  - Burhan H
PY  - 2026
JO  - BMJ open respiratory research
DO  - 10.1136/bmjresp-2026-004232
UR  - https://doi.org/10.1136/bmjresp-2026-004232
ER  - 

APA

R, B., M, P., F, F., L, L., H, J., & H, B. (2026). Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success.. BMJ open respiratory research. https://doi.org/10.1136/bmjresp-2026-004232

Source records